Ambrogio Martina, Cappannoli Luigi, Rosati Erica, De Luca Gianmarco, Chiuchiarelli Marta, Spasiano Andrea, Urciuolo Federica, Cutoli Salvatore Lucio, De Pascale Gennaro, Cingolani Antonella, Grandaliano Giuseppe, Panocchia Nicola
Università Cattolica del Sacro Cuore, Rome, Italy.
Infective Disease Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
G Ital Nefrol. 2025 Apr 29;42(2):2025-vol2. doi: 10.69097/42-02-2025-08.
This study evaluated the causes of and risk factors for mortality among patients on chronic HD hospitalised with SARS-CoV-2; in particular, it evaluated whether the cause of death was directly related to coronavirus disease 2019 (Covid-19) or another pathology. The European Renal Association registry showed a 20% mortality rate after 28 days for these patients. The clinical data of chronic HD patients hospitalised because of SARS-CoV-2 at the Fondazione Policlinico Universitario Agostino Gemelli from 15 March 2020 to 28 February 2022 were analysed. Univariate and multivariate regression analyses were performed to identify risk factors for mortality. The causes of mortality were obtained from the hospital discharge forms. One hundred fifty-two patients on maintenance haemodialysis with positive SARS-CoV-2 test results were hospitalised during the study period. There were 100 male (65.8%) and 52 female (34.2%) patients (mean age, 69 years; standard deviation [SD], 14.14 years). The mean Charlson comorbidity index (CCI) was 6.44 (SD, 2.64), and the average hospitalisation length was 23.57 days (SD, 24.55 days). Forty-two (27.6%) patients died, but only 22 deaths (59%) were directly caused by Covid-19. Only 59% of the deaths of patients with positive Covid-19 test results were directly caused by Covid-19. The survival of patients on chronic HD is independently related to specific patient characteristics (age, CCI, presence of peripheral vascular disease, and intensive care unit admission), but not to Covid-19.
本研究评估了因感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)而住院的慢性血液透析(HD)患者的死亡原因及危险因素;特别是,评估了死亡原因是否与2019冠状病毒病(Covid-19)或其他病理状况直接相关。欧洲肾脏协会登记处显示,这些患者28天后的死亡率为20%。对2020年3月15日至2022年2月28日期间在阿戈斯蒂诺·杰梅利大学综合医院因SARS-CoV-2住院的慢性HD患者的临床数据进行了分析。进行单因素和多因素回归分析以确定死亡危险因素。死亡原因来自医院出院表格。在研究期间,152例SARS-CoV-2检测呈阳性的维持性血液透析患者住院。其中男性100例(65.8%),女性52例(34.2%)(平均年龄69岁;标准差[SD]为14.14岁)。平均查尔森合并症指数(CCI)为6.44(SD为2.64),平均住院时间为23.57天(SD为24.55天)。42例(27.6%)患者死亡,但只有22例死亡(59%)是由Covid-19直接导致的。Covid-19检测呈阳性的患者中,只有59%的死亡是由Covid-19直接导致的。慢性HD患者的生存与特定的患者特征(年龄、CCI、外周血管疾病的存在以及入住重症监护病房)独立相关,而与Covid-19无关。